Skip to main content

Table 4 Comparison between group I (control group) and group II (case group) regarding levels of hemoglobin, AST, ALT, albumin, total bilirubin, INR, platelets, and creatinine 4 weeks after treatment

From: Effectiveness and safety of ombitasvir/paritaprevir/ritonavir in treatment of chronic hepatitis C Egyptian hemodialysis patients, case-control study

  Group I Group II Test value p value
Hemoglobin (gm/dl) Mean ± SD 12.63 ± 1.59 10.27 ± 1.97 6.581 0.001
Range 8.8–16 7.1–15.1
AST (U/L) Normal 49 (98.0%) 47 (94%) 1.042 0.307
High 1 (2%) 3 (6%)
ALT (U/L) Normal 45 (90%) 47 (94%) 0.543 0.461
High 5(10%) 3(6%)
Albumin (gm/dl) Mean ± SD 4.26 ± 0.40 4.03 ± 0.57 2.261 0.026
Range 3.2–5.4 2.7–5.3
Bilirubin (mg/dl) Mean ± SD 0.99 ± 0.43 0.73 ± 0.33 3.324 0.001
Range 0.2–2 0.2–2
INR Mean ± SD 1.08 ± 0.13 1.05 ± 0.08 1.197 0.234
Range 1–1.65 0.9–1.21
Platelets (103/mm3) Mean ± SD 250.27 ± 92.85 213.56 ± 69.12 2.234 0.028
Range 132–663 92–430
Creatinine (mg/dl) Median (IQR) 0.88 (0.7–0.95) 7.38 (5.6–9) − 8.634 0.001
Range 0.3–1.2 3–16.8